Krempf, Michel

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 2,985

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 2,724

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 2,296

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.

Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 1,237

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 850

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 232

High protein intake reduces intrahepatocellular lipid deposition in humans

Bortolotti, M., Kreis, R., Debard, C., Cariou, B., Faeh, D., Chetiveaux, M., Ith, M., Vermathen, P., Stefanoni, N., Lê, K.-A., et al. (2009) · The American Journal of Clinical Nutrition

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 146

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells

Lalanne, F., Lambert, G., Amar, M. J. A., Chétiveaux, M., Zaïr, Y., Jarnoux, A.-L., Ouguerram, K., Friburg, J., Seidah, N. G., Brewer, H. B., et al. (2005) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 104

Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)

Krempf, M., Parhofer, K. G., Steg, P. G., Bhatt, D. L., Ohman, E. M., Röther, J., Goto, S., Pasquet, B., & Wilson, P. W. F. (2010) · The American Journal of Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsAcute Ischemic Stroke Management

Cited by 82

Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes

Ouguerram, K., Magot, T., Zäir, Y., Marchini, J. S., Charbonnel, B., Laouenan, H., & Krempf, M. (2003) · The Journal of Pharmacology and Experimental Therapeutics

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 44

Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study

Blanchard, V., Ramin-Mangata, S., Billon-Crossouard, S., Aguesse, A., Durand, M., Chemello, K., Nativel, B., Flet, L., Chétiveaux, M., Jacobi, D., et al. (2018) · Journal of Lipid Research

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 43

A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1

The French Research Network on ADH, Marques-Pinheiro, A., Marduel, M., Rabès, J.-P., Devillers, M., Villéger, L., Allard, D., Weissenbach, J., Guerin, M., Zair, Y., et al. (2010) · European Journal of Human Genetics

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 38

Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects

Ouguerram, K., Maugeais, C., Gardette, J., Magot, T., & Krempf, M. (2006) · British Journal of Nutrition

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 31